RLYB
Rallybio Corp
NASDAQ · Healthcare · Biotechnology · US
$15.90
+0.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 434.0K | 858.0K | 636.0K | — | — |
| Cost of Revenue | 3.7M | 92.0K | 39.5M | 150.0K | — |
| Gross Profit | (3.2M) | 766.0K | (38.9M) | (150.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 5.1M | 19.6M | 41.5M | 53.5M | 40.7M |
| SG&A Expense | 16.8M | 14.3M | 18.3M | 25.4M | 27.2M |
| General & Admin Expense | 16.8M | 14.3M | 18.3M | 25.4M | 27.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (4.9M) | (5.1M) | (38.2M) | — | — |
| Total Operating Expenses | 17.0M | 28.8M | 21.6M | 78.9M | 67.9M |
| Cost and Expenses | 20.7M | 28.9M | 61.1M | 78.9M | 67.9M |
| Operating Income (EBIT) | (20.2M) | (28.1M) | (60.5M) | (78.9M) | (67.9M) |
| Non-Operating | |||||
| Interest Income | 1.8M | 2.2M | 4.2M | 6.1M | 2.0M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.8M | 2.2M | 4.2M | 6.1M | 2.0M |
| Other Non-Op Income/Expense | 48.4M | 19.1M | 2.7M | 4.4M | 1.2M |
| Non-Operating Income (excl Interest) | (51.4M) | — | — | — | — |
| EBT (Pre-Tax Income) | 28.2M | (9.0M) | (57.8M) | (74.6M) | (66.7M) |
| Income Tax Expense | 1.4M | — | — | — | — |
| Bottom Line | |||||
| Net Income | 26.8M | (9.0M) | (57.8M) | (74.6M) | (66.7M) |
| Earnings from Cont. Ops | 26.8M | (9.0M) | (57.8M) | (74.6M) | (66.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 26.8M | (9.0M) | (57.8M) | (74.6M) | (66.7M) |
| Per Share | |||||
| Basic EPS | $4.61 | ($1.59) | ($10.64) | ($14.72) | ($16.72) |
| Diluted EPS | $4.48 | ($1.59) | ($10.64) | ($14.72) | ($16.72) |
| Revenue Per Share | $0.08 | $0.15 | $0.12 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.7M | 5.6M | 5.4M | 5.1M | 4.0M |
| Diluted Shares Outstanding | 5.7M | 5.6M | 5.4M | 5.1M | 4.0M |
| Profitability Metrics | |||||
| EBITDA | 31.2M | (28.0M) | (60.4M) | (78.8M) | (67.7M) |
| D&A | 8.0K | 92.0K | 131.0K | 150.0K | 167.0K |
| EBIT | 31.2M | (28.1M) | (60.5M) | (78.9M) | (67.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026